Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas:

Abstract

Objectives

A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lymphoma (cHL). In this retrospective analysis, we aimed to assess this therapy’s efficacy in unselected patients with cHL and CD30+ peripheral T cell lymphoma (PTCL).

Patients and methods

Data of 28 patients with cHL and 5 patients with PTCL treated with a combination of bendamustine and BV at three Austrian tertiary cancer centers were analyzed.

Results

In patients with cHL, the ORR was 100% (78.6% CR, 21.4% PR). After 17 months median follow‐up, median survival times were not reached; 1‐year‐PFS was 81.9% and 1‐year‐OS was 95.7%. Thirteen eligible patients (46.4%) successfully underwent planned ASCT after salvage therapy with bendamustine and BV and subsequent high dose chemotherapy.

Three of the five PTCL patients achieved CR, while two did not respond and died during or shortly after therapy.

Conclusion

A combination of bendamustine and BV is an effective salvage and induction therapy before ASCT in patients with relapsed/refractory cHL. Further research is warranted to evaluate the use in patients with PTCL.